Article in Viruses, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.8field-weighted citation impact, top 14% of its field
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literature
Who cites it
5 citing papers in PubMed, 8 citations in OpenAlex.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
11 authors at 4 institutions in 3 countries.
Abhishek AsthanaCancer Biology, Lerner Research Institute, Cleveland Clinic, 2111 East 96th St, Cleveland, OH 44106, USA.
Angela CoronaLaboratorio di Virologia Molecolare, Dipartimento di Scienze della Vita e Dell'Ambiente, Universitá degli Studi di Cagliari, Cittadella Universitaria di Monserrato SS554, 09042 Monserrato, Italy.ORCID 0000-0002-6630-8636
Woo-Jin ShinCancer Biology, Lerner Research Institute, Cleveland Clinic, 2111 East 96th St, Cleveland, OH 44106, USA.
Mi-Jeong KwakCancer Biology, Lerner Research Institute, Cleveland Clinic, 2111 East 96th St, Cleveland, OH 44106, USA.
Christina GaughanCancer Biology, Lerner Research Institute, Cleveland Clinic, 2111 East 96th St, Cleveland, OH 44106, USA.ORCID 0000-0002-0869-9026
Enzo TramontanoLaboratorio di Virologia Molecolare, Dipartimento di Scienze della Vita e Dell'Ambiente, Universitá degli Studi di Cagliari, Cittadella Universitaria di Monserrato SS554, 09042 Monserrato, Italy.ORCID 0000-0002-4849-0980
Jae U JungCancer Biology, Lerner Research Institute, Cleveland Clinic, 2111 East 96th St, Cleveland, OH 44106, USA.
Rainer SchobertOrganic Chemistry 1, University of Bayreuth, Universitätsstrasse 30, 95440 Bayreuth, Germany.ORCID 0000-0002-8413-4342
Babal Kant JhaCenter for Immunotherapy and Precision Immuno-Oncology, Lerner Research Institute and Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, 2111 East 96th St, Cleveland, OH 44195, USA.ORCID 0000-0002-7660-5255
Robert H SilvermanCancer Biology, Lerner Research Institute, Cleveland Clinic, 2111 East 96th St, Cleveland, OH 44106, USA.
Bernhard BiersackOrganic Chemistry 1, University of Bayreuth, Universitätsstrasse 30, 95440 Bayreuth, Germany.ORCID 0000-0001-7305-346X
Cleveland Clinic Lerner College of Medicine · USUniversity of Bayreuth · DEUniversity of Cagliari · ITCleveland Clinic · US
Funding
Control of Viral Pathogenesis by Regulation of 2-5A LevelsR01AI104887 · NIAID · UNIVERSITY OF PENNSYLVANIA · PI SILVERMAN, ROBERT H., WEISS, SUSAN R · 2013 to 2023
$7.6M
KSHV Subunit Vaccine Candidates to Elicit Potent Humoral Immune Reponses against KSHV InfectionR01AI151013 · NIAID · BECKMAN RESEARCH INSTITUTE/CITY OF HOPE · PI OGEMBO, JAVIER GORDON · 2021 to 2025
$4.3M
SFTSV nonstructural protein NSs-mediated immunopathogenesisR01AI140705 · NIAID · UNIVERSITY OF SOUTHERN CALIFORNIA · PI JUNG, JAE U · 2018 to 2022
$4.2M
Eltombopag: Novel Mode of Action on Normal and Aplastic Anemia Hematopoietic Stem CellsR01DK131923 · NIDDK · CLEVELAND CLINIC LERNER COM-CWRU · PI Babal K Jha, Jaroslaw P. Maciejewski · 2022 to 2026
$3.3M
Targeting TET DNA Dioxygenases as Therapeutic Principle in Myeloid NeoplasmsR01CA257544 · NCI · CLEVELAND CLINIC LERNER COM-CWRU · PI JHA, BABAL K, MACIEJEWSKI, JAROSLAW P. · 2021 to 2025
$3.0M
Reassortment of Bunyavirus in ticks and animal modelsR01AI171201 · NIAID · CLEVELAND CLINIC LERNER COM-CWRU · PI Jae U Jung · 2022 to 2026
$2.9M
Tickborne SFTS Virus Vaccine DevelopmentR01AI152190 · NIAID · CLEVELAND CLINIC LERNER COM-CWRU · PI JUNG, JAE U · 2020 to 2024
Viral replication often depends on RNA maturation and degradation processes catalyzed by viral ribonucleases, which are therefore candidate targets for antiviral drugs. Here, we synthesized and studied the antiviral properties of a novel nitrocatechol compound (
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Analogs of the Catechol Derivative Dynasore Inhibit HIV-1 Ribonuclease H, SARS-CoV-2 nsp14 Exoribonuclease, and Virus Replication. · full record | OpenQuestion